Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (relapsed/refractory) | Do not reimburse | Complete | ||
| Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete | ||
| Votrient | Pazopanib Hydrochloride | Soft Tissue Sarcoma | Do not reimburse | Complete | ||
| Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Do not list | Complete | ||
| Lucentis | Ranibizumab injection | Macular edema, secondary to retinal vein occlusion | List with clinical criteria and/or conditions | Complete | ||
| Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete | ||
| Xalkori | Crizotinib | Advanced Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
| Mozobil | Plerixafor | Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma | Do not list | Complete | ||
| Afinitor | Everolimus | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onbrez | Indacaterol | Chronic obstructive pulmonary disease | List in a similar manner | Complete |
Last Updated : May 16, 2024